治療抵抗性うつ病の世界市場

治療抵抗性うつ病の世界市場は2030年までに23億米ドルに到達

2024年に18億米ドルと推定される治療抵抗性うつ病の世界市場は、2024年から2030年にかけてCAGR 3.5％で成長し、2030年には23億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗うつ薬は、CAGR 4.7％を記録し、分析期間終了時には8億1,230万米ドルに達すると予測されます。選択的セロトニン再取り込み阻害薬セグメントの成長率は、分析期間中CAGR 2.4%と推定されます。

米国市場は5億340万米ドルと推定、中国はCAGR6.7％で成長予測

米国の治療抵抗性うつ病市場は、2024年に5億340万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億5,830万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.7%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界の「治療抵抗性うつ病」市場- 主要動向と促進要因のまとめ

治療抵抗性うつ病が世界のメンタルヘルス論議で急務となっているのはなぜか？

治療抵抗性うつ病（TRD）は、世界のメンタルヘルスの状況において最も差し迫った複雑な課題の1つとして浮上しており、少なくとも2種類の標準的な抗うつ薬治療で十分な効果が得られない数百万人に影響を及ぼしています。うつ病はすでに世界の身体障害の主要な原因のひとつであるが、TRDはその慢性性、高い再発率、機能障害、入院、自殺との強い関連性により、ヘルスケアシステムの負担を著しく増大させています。TRDに対する認識の高まりは、臨床医がうつ病を評価し、層別化する方法にパラダイムシフトをもたらし、新しい診断基準や患者報告アウトカムを取り入れることで、抵抗性のある症例を早期に発見できるようになりました。従来のSSRIやSNRIは一部の患者には効果がないことが多いという認識が広まり、新規の薬理学的・非薬理学的治療に対する需要が高まっています。メンタルヘルスが公共政策の最前線に躍り出るにつれ、特にCOVID-19の大流行による心理的影響を考慮すると、TRDは資金調達、技術革新、規制の面で優先的に注目されるようになっています。患者アドボカシー、スクリーニングツールの改善、社会的な汚名返上キャンペーンもまた、TRDを影から追い出し、その管理により積極的で集学的なアプローチを促進しつつあります。

画期的な治療薬はTRD治療の展望をどのように再定義しているのか？

TRD治療のエコシステムは、従来のモノアミン系抗うつ薬の限界に課題する新規治療薬の承認と開発によって、急速な変貌を遂げつつあります。このような画期的な新薬の最たるものが、ケタミンから誘導された点鼻薬であるエスケタミンです。エスケタミンは複数の市場で承認され、TRD患者において迅速かつ臨床的に有意な症状緩和を示しました。従来の抗うつ薬とは異なり、エスケタミンはグルタミン酸作動系に作用するため、治療が難しいことで知られるTRDに新たな作用機序をもたらします。サイケデリック補助療法、特にシロシビンやMDMAを用いた治療法も普及しつつあり、臨床試験では、抵抗性のある症例でも持続的な寛解を促す有望な結果が得られています。これと並行して、経頭蓋磁気刺激法（TMS）、迷走神経刺激法（VNS）、脳深部刺激法（DBS）などの神経調節技術は、薬物療法に反応しないTRD患者に対する実行可能な選択肢として発展しつつあります。遺伝子やバイオマーカーに基づくアプローチは、臨床医が薬物反応を予測し、より効果的に治療を調整するのに役立っています。デジタル治療薬や遠隔モニタリングツールも普及しつつあり、認知行動支援、アドヒアランス追跡、リアルタイムの気分評価などを提供することで、薬物治療を補強し、再発を減らすことができます。

TRDの影響を最も受けるヘルスケアシステムと人口統計は？

TRDは高所得国のヘルスケアシステムに不釣り合いなほど大きな負担をもたらします。北米と西欧では、TRDは精神衛生関連の入院、障害請求、長期薬物療法費用の大きな割合を占めています。また、これらの地域では診断精度が高く、先進的な治療法へのアクセスも容易であるため、新しい治療法をいち早く採用しています。しかし、TRDの罹患率は、経済的困難、都市ストレス、社会的孤立が精神衛生上の脆弱性を悪化させている東欧、ラテンアメリカ、アジア太平洋の一部などの中所得地域を含め、世界的に上昇しています。人口統計学的に、TRDはあらゆる年齢層に影響を及ぼすが、35～60歳の成人、女性、不安障害や糖尿病や心血管疾患などの慢性的な身体疾患を合併している人において有病率が高いです。TRDの発症と持続には、失業、トラウマ歴、社会的支援の欠如など、健康の社会的決定要因も重要な役割を果たしています。認知度が向上するにつれて、長期的な負担を軽減し、治療抵抗性を生じさせないために、早期介入、統合ケアモデル、地域に根ざしたメンタルヘルスサービスが重視されるようになってきています。

治療抵抗性うつ病市場の成長はいくつかの要因に牽引されている...

治療抵抗性うつ病市場は、臨床的、技術的、社会的促進要因の合流によって急速に拡大しています。最も大きな要因の1つは、標準的な抗うつ薬に反応しない大うつ病性障害と診断された患者数の増加であり、より効果的な代替薬に対する緊急のニーズが生じています。エスケタミンのような革新的な治療薬が規制当局から承認され、サイケデリック化合物が臨床的に成功しつつあることで、新たな治療カテゴリーが開拓され、投資が集まり、研究開発パイプラインが加速しています。これと並行して、脳画像、ゲノム、AIを活用した診断の進歩により、うつ病のサブタイプをより正確に層別化できるようになり、臨床医がより早く、より正確に抵抗性のある症例をターゲットにできるようになっています。ヘルスケアシステムは、アウトカムの有効性を重視する価値ベースのケアモデルを採用するようになってきており、TRDに対する即効性と持続性のある治療法の使用にインセンティブを与えています。患者アドボカシーと精神医療のデスティグマティゼーションは、患者が助けを求め、治療計画を遵守することをさらに促し、対処可能な市場を拡大しています。また、神経調節やデジタル治療などの新しい治療法に対する保険償還も改善されつつあり、多様な患者グループへのアクセスが向上しています。さらに、TRDの長期的な経済的負担（生産性の低下、身体障害、医療利用の再発など）は、政府や民間医療提供者に、この市場における技術革新と資源配分の優先順位を押し上げています。その結果、TRDは臨床上の課題から、世界のメンタルヘルスケアに大きな影響を与える成長分野へと進化しつつあります。

セグメント

薬剤タイプ（抗うつ薬、選択的セロトニン再取り込み阻害薬、セロトニン・ノルエピネフリン再取り込み阻害薬、非定型薬、その他の薬剤タイプ）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全34件）

• AbbVie Inc.
• ACADIA Pharmaceuticals
• Alkermes plc
• AstraZeneca plc
• Axsome Therapeutics
• Beckley Psytech
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Celon Pharma S.A.
• COMPASS Pathways plc
• Eli Lilly and Company
• GH Research PLC
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Janssen Pharmaceuticals
• Navitor Pharmaceuticals
• Novartis International AG
• Otsuka Pharmaceutical Co., Ltd.
• Relmada Therapeutics
• SAGE Therapeutics

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Treatment Resistant Depression Market to Reach US$2.3 Billion by 2030

The global market for Treatment Resistant Depression estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$812.3 Million by the end of the analysis period. Growth in the Selective Serotonin Reuptake Inhibitors segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$503.4 Million While China is Forecast to Grow at 6.7% CAGR

The Treatment Resistant Depression market in the U.S. is estimated at US$503.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$458.3 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global "Treatment Resistant Depression" Market - Key Trends & Drivers Summarized

Why Is Treatment-Resistant Depression Gaining Urgency in Global Mental Health Discussions?

Treatment-resistant depression (TRD) has emerged as one of the most pressing and complex challenges in the global mental health landscape, impacting millions of individuals who fail to respond adequately to at least two standard antidepressant therapies. With depression already among the leading causes of disability worldwide, TRD significantly compounds the burden on healthcare systems due to its chronicity, high relapse rates, and strong association with functional impairment, hospitalization, and suicide. The rising awareness of TRD has led to a paradigm shift in how clinicians assess and stratify depression, incorporating new diagnostic criteria and patient-reported outcomes to identify resistant cases earlier. The growing recognition that conventional SSRIs and SNRIs often prove ineffective for a subset of patients is catalyzing a demand for novel pharmacological and non-pharmacological treatments. As mental health moves to the forefront of public policy-particularly in light of the psychological fallout from the COVID-19 pandemic-TRD is being prioritized for funding, innovation, and regulatory attention. Patient advocacy, better screening tools, and public destigmatization campaigns are also bringing TRD out of the shadows, fostering a more proactive, multidisciplinary approach to its management.

How Are Breakthrough Therapies Redefining the TRD Treatment Landscape?

The TRD treatment ecosystem is undergoing rapid transformation, driven by the approval and development of novel therapeutics that challenge the limitations of traditional monoamine-based antidepressants. Foremost among these breakthroughs is esketamine, a nasal spray derived from ketamine, which has received regulatory approval in multiple markets and demonstrated rapid, clinically significant symptom relief in TRD patients. Unlike conventional antidepressants, esketamine works on the glutamatergic system, offering a new mechanism of action for a notoriously difficult-to-treat condition. Psychedelic-assisted therapies-particularly those involving psilocybin and MDMA-are also gaining ground, with clinical trials showing promising results in promoting sustained remission in otherwise resistant cases. In parallel, neuromodulation techniques such as transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS) are evolving as viable options for TRD patients unresponsive to medication. Personalized medicine is playing a growing role, with genetic and biomarker-based approaches helping clinicians predict drug response and tailor treatments more effectively. Digital therapeutics and remote monitoring tools are also gaining traction, offering cognitive behavioral support, adherence tracking, and real-time mood assessments that can augment pharmacological treatments and reduce relapse.

Which Healthcare Systems and Demographics Are Most Affected by TRD?

TRD poses a disproportionately high burden on healthcare systems in high-income countries, where mental health infrastructure is more robust but also more strained by demand. In North America and Western Europe, TRD accounts for a significant share of mental health-related hospitalizations, disability claims, and long-term pharmacotherapy expenses. These regions also see higher diagnostic accuracy and access to advanced therapies, making them early adopters of new treatment modalities. However, the incidence of TRD is rising globally, including in middle-income regions such as Eastern Europe, Latin America, and parts of Asia-Pacific, where economic hardship, urban stress, and social isolation are exacerbating mental health vulnerabilities. Demographically, TRD affects individuals across age groups but shows elevated prevalence in adults aged 35-60, women, and individuals with comorbid anxiety disorders or chronic physical illnesses such as diabetes and cardiovascular disease. Social determinants of health-such as unemployment, trauma history, and lack of social support-also play a critical role in TRD onset and persistence. As awareness improves, there is growing emphasis on early intervention, integrated care models, and community-based mental health services to reduce the long-term burden and prevent treatment resistance from developing.

The Growth in the Treatment Resistant Depression Market Is Driven by Several Factors…

The treatment-resistant depression market is expanding rapidly due to a confluence of clinical, technological, and societal drivers. One of the foremost factors is the growing patient population diagnosed with major depressive disorder who do not respond to standard antidepressants, creating an urgent need for more effective alternatives. Regulatory approvals of innovative therapies like esketamine and ongoing clinical success of psychedelic compounds are opening new therapeutic categories, attracting investment and accelerating R&D pipelines. In parallel, advances in brain imaging, genomics, and AI-driven diagnostics are enabling more precise stratification of depression subtypes, helping clinicians target resistant cases earlier and more accurately. Healthcare systems are increasingly adopting value-based care models that emphasize outcome efficacy, thereby incentivizing the use of fast-acting and durable treatments for TRD. Patient advocacy and mental health destigmatization are further encouraging individuals to seek help and adhere to treatment plans, enlarging the addressable market. Insurance reimbursement for newer therapies, including neuromodulation and digital therapeutics, is also improving, enhancing access across diverse patient groups. Moreover, the long-term economic burden of TRD-measured in lost productivity, disability, and recurrent healthcare utilization-is pushing governments and private healthcare providers to prioritize innovation and resource allocation in this market. As a result, TRD is evolving from a clinical challenge to a high-impact growth sector in global mental healthcare.

SCOPE OF STUDY:

The report analyzes the Treatment Resistant Depression market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• ACADIA Pharmaceuticals
• Alkermes plc
• AstraZeneca plc
• Axsome Therapeutics
• Beckley Psytech
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Celon Pharma S.A.
• COMPASS Pathways plc
• Eli Lilly and Company
• GH Research PLC
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Janssen Pharmaceuticals
• Navitor Pharmaceuticals
• Novartis International AG
• Otsuka Pharmaceutical Co., Ltd.
• Relmada Therapeutics
• SAGE Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Treatment Resistant Depression - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Diagnosis of Mental Health Disorders Expands Treatment Demand
  • Limitations of Traditional Therapies Propel Demand for Novel Treatments
  • Rising Awareness and Advocacy Strengthen Business Case for Innovation
  • Growing Use of Ketamine and Esketamine Spurs Market Growth
  • Advances in Neurostimulation Therapies Drive Product Development
  • Digital Mental Health Tools and Telepsychiatry Accelerate Treatment Access
  • Expanding Pipeline of Novel Antidepressants Generates Hope and Investment
  • Favorable Reimbursement Policies in Developed Markets Drive Adoption
  • Genetic and Biomarker Research Strengthens Personalized Treatment Approaches
  • Stigma Reduction and Workplace Programs Sustain Market Expansion
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Treatment Resistant Depression Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Treatment Resistant Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Selective Serotonin Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Selective Serotonin Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Serotonin-Norepinephrine Reuptake Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Atypical Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Atypical Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Atypical Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Japan 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: China 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: China 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Treatment Resistant Depression by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Europe 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: France 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: France 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Germany 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Germany 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Italy 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Italy 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: UK 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: UK 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Spain 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Spain 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Russia 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Russia 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Treatment Resistant Depression by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Australia 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Australia 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 119: India Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: India 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 122: India Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: India 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: South Korea 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: South Korea 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Treatment Resistant Depression by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Latin America 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Latin America 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Latin America 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Argentina 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Argentina 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Brazil 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Brazil 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Mexico 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Mexico 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Treatment Resistant Depression by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Middle East 15-Year Perspective for Treatment Resistant Depression by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Middle East 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Middle East 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Iran 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Iran 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Israel 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Israel 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: UAE 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: UAE 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Treatment Resistant Depression Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Treatment Resistant Depression by Drug Type - Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Africa 15-Year Perspective for Treatment Resistant Depression by Drug Type - Percentage Breakdown of Value Sales for Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Atypical Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Treatment Resistant Depression by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Africa 15-Year Perspective for Treatment Resistant Depression by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION